Our Strategic
Priorities

More energy –
Growing and delivering

More energy – Growing and delivering, Idorsia

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. To achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core.

We have identified five key strategic priorities to ensure the company’s success over the first 5 years.

Jean-Paul Clozel, Idorsia

Promising compounds

Promising compounds, Idorsia

Idorsia aims to deliver at least three products to market with the potential to significantly change treatment options in their target disease, resulting in assets with major commercial potential.

We have a diversified and balanced clinical development pipeline covering multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

We bring new perspectives to the development of innovative compounds, challenging accepted paradigms to answer the questions that matter to patients. Our key assets have the potential to transform treatment in the target indications.

“With patients at the heart of our process, our key assets have the potential to transform treatment in the target indications.”

- Guy Braunstein, Head of Global Clinical Development

From bench to bedside

From bench to bedside, Idorsia

Idorsia aims to build a commercial organization to maximize the value of our innovations.

A long-term strategic perspective is vital to ensure that our drugs address important healthcare challenges. A smart company must adopt creative approaches to delivering its medicines to patients.

To maximize the benefit of our pioneering therapies for patients, we will consider strategic partnerships and build our own commercial infrastructure to provide access to our drugs in certain therapeutic fields.

“Idorsia has the ideal constellation for bringing successful medicines to the market.”

- Jean-Paul Clozel, CEO

Becoming a sustainable company

Becoming a sustainable company, Idorsia

Idorsia’s highly qualified professionals aim to rapidly advance the development pipeline and commercial readiness, so as to bring Idorsia to profitability within 5 years.

We are building Idorsia with a long-term focus and ambitious aspirations. We will run the company in a responsible and sustainable way. Becoming profitable will provide us with financial independence and secure our future.

Idorsia has the potential to generate significant revenues from product sales once the first of its pipeline candidates has received regulatory approval for commercialization. In the meantime, Idorsia has generated revenue through a milestone payment from its collaboration with Janssen on the co-development and commercialization of aprocitentan; this collaboration could also generate royalty payments. Furthermore, Idorsia could benefit from revenue-sharing payments relating to potential sales of ponesimod.

We are providing a supportive and stimulating environment for high-performing teams, recognizing and rewarding their contributions.

“We have a diverse pipeline with unique assets that have significant potential for patients. We must invest in this pipeline in order to make Idorsia a profitable company, in a sustainable manner.”

- André C. Muller, CFO

Building a bright future

insomnia gets in the way of everything

Idorsia aims to create a clinical development pipeline of assets with a sales potential of at least CHF 5 billion.

Idorsia is a high-potential biopharmaceutical company with a balanced portfolio of innovative drugs. As our assets advance and reach the market, there is a need to constantly replenish the pipeline with innovative compounds. This is where our highly productive drug discovery engine creates opportunities.

We are passionate and curious scientists, determined to help patients function better, feel better and live longer. Our drug discovery focuses on creating small molecules that are active on well-selected molecular targets. Knowledge built through the development of drugs active on one target can often benefit projects in several therapeutic areas.

Our focus on disorders with a high medical need means that our discoveries create significant value for patients, payors and society in general.

“Our approach: novel projects that answer medical problems in groundbreaking ways balanced with less risky projects where we have a deep understanding of the disease mechanisms.”

- Martine Clozel, CSO

Utilize state-of-the-art technologies

Utilize state-of-the-art technologies, Idorsia

Idorsia aims to increasingly utilize state-of-the-art technologies to aid discovery, development and commercialization of our innovative therapies.

As we want to remain at the cutting edge of science, it is vital that we consider innovative approaches from bench to bedside. We must integrate computational tools and digital technologies at different stages of the drug discovery, development and commercialization process, to maximize our potential and bring breakthrough medicines to patients.

Idorsia will look for creative ways to harness advances in technology to focus on novel targets and use new drug development methods. All functions of Pharmaceutical Development are streamlined to ensure the delivery of technically tailored and high-quality medicines. As the company establishes its commercial infrastructure, we will look for opportunities to use technology to benefit as many patients as possible.

When it comes to our colleagues’ daily life at Idorsia, we also employ pragmatic solutions to minimize the need for bureaucracy. Continuous learning and work-life balance are important engagement drivers to ensure that everyone thrives at Idorsia.

“We must integrate computational tools and digital technologies at every stage of the drug discovery, clinical development, and commercialization process, in order to maximize our potential to bring breakthrough medicines to patients.”

- Jean-Paul Clozel, CEO